Amgen (AMGN)
(Real Time Quote from BATS)
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:42 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:08 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:42 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:08 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Exxon Mobil, S&P Global, HSBC and LULU
Stock Market News for Oct 6, 2020
by Zacks Equity Research
Benchmarks closed higher on Monday as markets cheered news of President Trump???s positive response to Covid-19 treatment, and discharge from hospital.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Simple Secrets Anyone Can Use to Reach Early Retirement - October 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Top Stock Reports for Amgen, Exxon Mobil & S&P Global
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Exxon Mobil (XOM) and S&P Global (SPGI).
Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
by Zacks Equity Research
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis
by Zacks Equity Research
FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.
The Extreme Risks of Trading Your Own Retirement Assets - September 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Simple Secrets Anyone Can Use to Reach Early Retirement - September 25, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
by Ritujay Ghosh
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies
by Zacks Equity Research
Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
The Extreme Risks of Trading Your Own Retirement Assets - September 14, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis
by Zacks Equity Research
J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.
Easy Investing Secrets to an Early Retirement - September 09, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
by Zacks Equity Research
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 04, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?
by Sanghamitra Saha
The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
Stock Market News for Sep1, 2020
by Zacks Equity Research
U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.
Lessons for Equity Investors From Dow Jones' Big Shake-Up
by Nilanjan Choudhury
The Dow Jones is a rare example of an index constructed on the basis of a component's share price.